BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11839677)

  • 1. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
    Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
    Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
    Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.
    Elad G; Paz A; Haklai R; Marciano D; Cox A; Kloog Y
    Biochim Biophys Acta; 1999 Dec; 1452(3):228-42. PubMed ID: 10590312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Ras antagonist blocks human melanoma growth.
    Jansen B; Schlagbauer-Wadl H; Kahr H; Heere-Ress E; Mayer BX; Eichler H; Pehamberger H; Gana-Weisz M; Ben-David E; Kloog Y; Wolff K
    Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14019-24. PubMed ID: 10570191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
    Weisz B; Giehl K; Gana-Weisz M; Egozi Y; Ben-Baruch G; Marciano D; Gierschik P; Kloog Y
    Oncogene; 1999 Apr; 18(16):2579-88. PubMed ID: 10353601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation.
    Gana-Weisz M; Haklai R; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
    Biochem Biophys Res Commun; 1997 Oct; 239(3):900-4. PubMed ID: 9367867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
    Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
    Int J Cancer; 1999 Mar; 80(6):911-8. PubMed ID: 10074926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
    Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
    J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dislodgment and accelerated degradation of Ras.
    Haklai R; Weisz MG; Elad G; Paz A; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
    Biochemistry; 1998 Feb; 37(5):1306-14. PubMed ID: 9477957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
    Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM
    Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
    Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
    Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis.
    Karussis D; Abramsky O; Grigoriadis N; Chapman J; Mizrachi-Koll R; Niv H; Kloog Y
    J Neuroimmunol; 2001 Nov; 120(1-2):1-9. PubMed ID: 11694313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stringent structural requirements for anti-Ras activity of S-prenyl analogues.
    Aharonson Z; Gana-Weisz M; Varsano T; Haklai R; Marciano D; Kloog Y
    Biochim Biophys Acta; 1998 Feb; 1406(1):40-50. PubMed ID: 9545527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
    Aizman E; Mor A; Levy A; George J; Kloog Y
    Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ras inhibitor S-trans, trans-farnesylthiosalicylic acid enhances spatial memory and hippocampal long-term potentiation via up-regulation of NMDA receptor.
    Wang Y; Chen T; Yuan Z; Zhang Y; Zhang B; Zhao L; Chen L
    Neuropharmacology; 2018 Sep; 139():257-267. PubMed ID: 29578035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
    Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y
    Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
    Erlich S; Tal-Or P; Liebling R; Blum R; Karunagaran D; Kloog Y; Pinkas-Kramarski R
    Biochem Pharmacol; 2006 Aug; 72(4):427-36. PubMed ID: 16780807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
    Barkan B; Kloog Y; Ehrlich M
    Mol Cancer Ther; 2011 Aug; 10(8):1317-26. PubMed ID: 21632464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
    Wolfson E; Schmukler E; Schokoroy ST; Kloog Y; Pinkas-Kramarski R
    Biol Cell; 2015 May; 107(5):130-43. PubMed ID: 25735913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.